Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study.
Torre E, Bruno GM, Di Matteo S, Martinotti C, Valentino MC, Bottaro LC, Colombo GL.
Torre E, et al.
Clinicoecon Outcomes Res. 2020 Apr 8;12:177-189. doi: 10.2147/CEOR.S240183. eCollection 2020.
Clinicoecon Outcomes Res. 2020.
PMID: 32308446
Free PMC article.
MATERIAL AND METHOD: In our analysis, we have applied the cost-utility technique to the above reported clinical outcomes and compared the global costs of dulaglutide versus sulfonylurea or basal insulin, all in add-on with metformin. We have chosen gliclazide, as a sulfonylurea a …
MATERIAL AND METHOD: In our analysis, we have applied the cost-utility technique to the above reported clinical outcomes and compared the gl …